<DOC>
	<DOC>NCT02877628</DOC>
	<brief_summary>Prospective, non-randomized, open Pharmacokinetic-Pharmacogenetic-Pharmacodynamic monocentric study. Donor and recipient CYP3A5 genotype and recipient ABCB1 will not be communicate to clinicians or patients during the study.</brief_summary>
	<brief_title>Immunosuppressive Therapy Optimization: Development of a Population Pharmacokinetic-pharmacodynamic (PK-PD) Model in Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Adults over 18 Liver transplant recipients Treated with an immunosuppressive protocol with tacrolimus Informed on the study and who did not refuse to participate Patients who participate in a study with procedures incompatible with the present study. Patients with legal protection/deprived of liberty.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>CYP3A5</keyword>
	<keyword>liver transplantation</keyword>
</DOC>